Autoimmune Bullous Diseases Part II: Subepidermal Autoimmune Bullous Dermatoses

Česká verzia

Authors: H. Jedličková
Authors place of work: I. dermatovenerologická klinika FNUSA a LF Masarykovy univerzity, Brno přednostka prof. MUDr. Hana Jedličková, Ph. D.
Published in the journal: Čes-slov Derm, 98, 2023, No. 4, p. 184-195
Category: Reviews (Continuing Medical Education)

Summary

Autoimmune bullous dermatoses (AIBD) are rare, potentially fatal diseases of the skin and mucous membranes. According to the level of blister formation, we divide them into the group of pemphigus withintraepidermal blister and the group with subepidermal blister, which includes bullous pemphigoid, pemphigoid gestationis, mucous membrane pemphigoid, linear IgA dermatosis, epidermolysis bullosa acquisita and dermatitis herpetiformis. This review discusses subepidermal AIBD, with a focus on current diagnostics and recommended therapy. Individual diseases are distinguished by target autoantigens, frequency, clinical picture, response to therapy and prognosis. It is very important to have comprehensive diagnostics that differentiates the individual types of the disease and determines the best therapeutic procedure.

Keywords:

bullous pemphigoid – pemphigoid gestationis – mucous membrane pemphigoid – linear IgA dermatosis – epidermolysis bullosa acquisita – dermatitis herpetiformis – diagnosis – therapy

Zdroje

AMBER, K. T., ZIKRY, J., HERTL, M. A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: Is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading? HLA., 2017, 89(3), p. 127–134. doi: 10.1111/tan.12960.
ANDERSEN, K. M., BATES, B. A., RASHIDI, E. A. etal. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohortstudy using data from the National COVID Cohort Collaborative. The Lancet Rheumatology, 2022, 4(1), p. e33–e41
ATZMONY, L., MIMOUNI, I., REITER, O. et al. Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis. J Am Acad Dermatol., 2017, 77, p. 691–699.
BERNETT, C. N., FONG, M., YADLAPATI, S. et al. Linear IGA Dermatosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Dostupné na www: https://www.ncbi.nlm. nih.gov/books/NBK526113/.
BISHERWAL, K., PANDHI, D., SINGAL, A., SHARMA, S. Infantile Bullous Pemphigoid Following Vaccination. Indian Pediatr., 2016, 53(5), p. 425–426.
BORRADORI, L., VAN BEEK, N., FELICIANI, C. et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol., 2022, 36(10), p. 1689–1704. doi: 10.1111/jdv.18220.
BUREŠ, J. Celiakie v roce 2018. Vnitř Lék., 2018, 64(6), s. 602–610.
COZZANI, E., DI ZENZO, G., GASPARINI, G. et al. Autoantibody Profile of a Cohort of 54 Italian Patients with Linear IgA Bullous Dermatosis: LAD-1 Denoted as a Major Auto-antigen of the Lamina Lucida Subtype. Acta Dermato-Venereologica, 2020, 100(4), p. 1–5. Dostupné na www: https://doi. org/10.2340/00015555-3415.
DOURMISHEV, L. A., GULEVA, D. V., MITEVA, L. G. Intravenous immunoglobulins: mode of action and indications in autoimmune and inflammatory dermatoses. Int J Inflamm., 2016, p. 3523057. doi: 10.1155/2016/3523057.
GENOVESE, G., DI ZENZO, G., COZZANI, E. New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update. Front Immunol., 2019,10, 1506. doi: 10.3389/fimmu.2019.01506.
GÖRÖG, A., ANTIGA, E., SÁRDY, M. et al. S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol., 2021, 35, p.1251–1277. Dostupné na www: https://doi. org/10.1111/jdv.17183.
HANUŠOVÁ, K., JEDLIČKOVÁ, H. Autoimunitní puchýřnatá onemocnění – současné možnosti diagnostiky. Alergie, 2018, 20(3), p. 170–177. Dostupné na www: https://www.frontiersin.org/articles/10.3389/fmed.2018.00362.
HÜBNER, F., SETTERFIELD, J., RECKE, A. et al. HLA alleles in British Caucasians with mucous membrane pemphigoid. Eye, 2018, 32(9), p. 1540–1541. doi: 10.1038/s41433-018-0092-5.
CHEN, X., ZHANG, Y., LUO, Z. et al. Prognostic factors for mortality in bullous pemphigoid: A systematic review and meta-analysis. PLoS One, 2022, 17(4), e0264705. doi: 10.1371/journal.pone.0264705.
IZUMI, K., BIEBER, K., LUDWIG, R. J. Current Clinical Trials in Pemphigus and Pemphigoid. Front Immunol., 2019, 10. doi: 10.3389/FIMMU.2019.00978.
JEDLICKOVA, H., HLUBINKA, M., PAVLIK, T. et al. Bullous pemphigoid and internal diseases – A case-control study. Eur J Dermatol., 2010, 20(1), p. 96–101. doi: 10.1684/ejd.2010.0805.
JEDLIČKOVÁ, H. Autoimunitní subepidermální dermatózy. In: Moderní farmakoterapie v dermatologii, 1. vydání. Praha: Maxdorf, 2020. s. 240– 262.
JOLY, P., BARICAULT, S., SPARSA, A. et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol., 2012, 132(8), p. 1998–2004. doi: 10.1038/jid.2012.35.
KOGA HIROSHI, PROST-SQUARCIONI, C., IWATA HIROAKI. et al. Epidermolysis Bullosa Acquisita: The 2019 Update. Frontiers in Medicine, 2019, 5.
KOMOROUSOVÁ, M., NOVÁK, M., CETKOVSKÁ, P. Případy bulózního pemfigoidu po očkování proti covidu-19. Čes-slov Derm, 2022, 97(3), p. 127–131.
KRIDIN, K., AHMED, A. R. Anti-p200 Pemphigoid: A Systematic Review. Front Immunol., 2019, 10, p. 2466. doi: 10.3389/fimmu.2019.02466.
LANDEGREN, N., ISHII, N., ARANDA-GUILLEN, M. et al. A gene-centric approach to biomarker discovery identifies transglutaminase 1 as an epidermal autoantigen. Proc Natl Acad Sci U S A, 2021, p. 118.
PINKOVÁ, B., BUČKOVÁ, H., JEDLIČKOVÁ, H., FEIT, J. Bulózní pemfigoid vyvolaný očkováním. Čes-slov Derm., 2013, 88(3), p. 128–131.
RASHID, H., LAMBERTS, A., BORRADORI, L. et al. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by theEuropean Academy of Dermatology and Venereology – Part I. J Eur Acad Dermatol Venereol., 2021, 35(9), p. 1750–1764. doi: 10.1111/jdv.17397.
SCHMIDT, E., RASHID, H., MARZANO, A. V. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II. J Eur Acad Dermatol Venereol., 2021. Dostupné na www: https://doi.org/10.1111/ jdv.17395.
SCHULZE, F., NEUMANN, K., RECKE, A. et al. Malignancies in pemphigus and pemphigoid diseases. J Invest Dermatol., 2015, 135(5), p. 1445–1447. doi: 10.1038/jid.2014.547.
SOLIMANI, F., POLLMANN, R., ISHII, N. et al. Diagnosis of anti-laminin ƴ-1 pemphigoid by immunoblot analysis. J Eur Acad Dermatol Venereol., 2019, 33. Dostupné na www: https://doi.org/10.1111/ jdv.15170.
ULRICHTS, P., GUGLIETTA, A., DREIER, T. et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest., 2018, 128(10), p. 4372–4386. doi: 10.1172/ JCI97911.
VAN BEEK, N., ZILLIKENS, D., SCHMIDT, E. Diagnosis of autoimmune bullous diseases. JDDG, 2018, 16(9), p. 1077–1091. doi: 10.1111/ddg.13637.